Biophytis FY25 net loss narrows 17% to EUR 7.8 million

  • Biophytis posted a 2025 net loss of EUR 7.8 million, narrowing 17%.
  • Operating loss improved 12% to EUR 7.45 million; financial result loss narrowed 62% to EUR 349,000.
  • Cash totaled EUR 190,000 at year-end; it said liquidity does not cover the next 12 months, with funding estimated through Sept. 30, 2026.
  • Debt and current liabilities fell 4% to EUR 11.94 million, as bond borrowings dropped 28% to EUR 4.27 million.
  • Management highlighted a Hong Kong joint venture for BIO101 in sarcopenia with up to $20 million over three years; Phase 3 launch targeted for 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.